Advance in the study of CD4~+CD25~+FOXP3~+ regulatory T cell in tumor immune evasion / 中国癌症杂志
China Oncology
; (12)2006.
Article
en Zh
| WPRIM
| ID: wpr-545290
Biblioteca responsable:
WPRO
ABSTRACT
As a distinct T cell subset with acknowledged specific function and marker, CD4+CD25+FOXP3+ regulatory T cells are thought to dampen T-cell immunity and to be the main obstacle tempering antitumor immunotherapy. Accumulating evidence has confirmed an increased pool of regulatory T cells both in the peripheral blood and the tumor microenvironment of cancer patients, which are indicative of disease progression, response to therapy, invasive phenotype and prognosis. Therefore, manipulation of regulatory T cells—including depletion, blocking trafficking into tumors, or reducing their differentiation and suppressive mechanisms—and concomitant stimulation of effector T cells, systemically or locally in tumors, represent new strategies for cancer treatment.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
China Oncology
Año:
2006
Tipo del documento:
Article